McKesson Corporation (NYSE: MCK) has announced a definitive agreement to acquire a controlling interest in Community Oncology Revitalization Enterprise Ventures, LLC (Core Ventures) for approximately $2.49 billion in cash, representing about 70% ownership. Core Ventures, created by Florida Cancer Specialists & Research Institute, LLC (FCS), is a business and administrative services organization. FCS physicians will retain a minority stake in Core Ventures.
Upon completion of the transaction, Core Ventures will become part of McKesson’s Oncology platform, with its financial results reported under the US Pharmaceutical segment. The deal is subject to customary closing conditions and regulatory approvals. FCS, which operates over 100 locations in Florida with more than 250 physicians and 280 advanced practice providers, will remain independently owned and join McKesson’s The US Oncology Network (The Network).
Brian Tyler, McKesson’s CEO, stated, “This acquisition advances our commitment to community-based oncology care by enhancing our Oncology platform. We aim to improve patient care and reduce costs while integrating FCS’s patient-first approach into our network, which is dedicated to advancing cancer care and patient outcomes.”
FCS has been providing comprehensive cancer care for over 40 years, including clinical trials, imaging, medical oncology, and more. Through this partnership, FCS will access McKesson’s advanced oncology care products and services.
Lucio N. Gordan, MD, president and managing physician at FCS, noted, “Our patients will benefit greatly from this transaction, enhancing access to high-quality, affordable care through our combined expertise.”
Nathan H. Walcker, CEO of FCS, added, “Joining The US Oncology Network represents a significant evolution for our practice. We are excited to partner with McKesson to further our shared mission of improving community-based cancer care and patient outcomes.”
